Je was op zoek naar: minimal residual disease (Engels - Maltees)

2 with gross residual disease.
2 b’marda residwali sostanzjali.

2 with or without gross residual disease.
2 bi jew mingħajr marda residwali sostanzjali.

subgroup analyses of efs and os response indicated that patients with minimal residual disease, dna hyperploidy, and those having received a purged bone marrow may not have benefited from dinutuximab immunotherapy.
analiżijiet ta’ sottogruppi ta’ rispons efs u os indikaw li pazjenti b’mard residwu minimu, dna hyperploidy, u dawk li rċivew mudullun imnaddaf, setgħu ma bbenefikawx minn immunoterapija b’dinutuximab.

retreatment should be given at that time if residual disease activity remains, otherwise retreatment should be delayed until disease activity returns.
kura mill-ġdid għandha tingħata f’dak il-waqt jekk tibqa’ l-attività residwali tal-marda, inkella kura mill-ġdid għandha tiġi ttardjata sakemm tirritorna l-attività tal-marda.

major cytogenetic response, haematological response, molecular response (evaluation of minimal residual disease), time to accelerated phase or blast crisis and survival are main secondary endpoints.
dejta tar- rispons qed jintwerew f’ tabella 3.

clinical study to evaluate minimal residual disease (mrd) for the assessment of the anti-leukaemic activity of ceplene plus low dose interleukin-2 in approximately 150 adult patients stratified by age greater or less than 60 years with acute myeloid leukemia in first complete remission.
studju kliniku biex jevalwa mard minimu residwu (mrd) għall- valutazzjoni ta 'attività antilewċemika ta' ceplene flimkien ma 'doża baxxa ta' interleukin- 2 f' madwar 150 pazjent adult stratifikati skont età ikbar jew inqas minn 60 sena b' lewċemija mjelojde akuta fl- ewwel remissjoni kompluta.

overall approximately 34% of patients were figo stage iii optimally debulked with gross residual disease, 40% stage iii sub-optimally debulked, and 26% were stage iv patients.
globalment madwar 34% ta’ pazjenti kienu figo stadju iii bi tneħħija ottimali b’marda residwa sostanzjali, 40% kienu stadju iii bi tneħħija inqas minn ottimali, u 26% kienu pazjenti ta’ stadju iv.

evaluate minimal residual disease (mrd) at baseline and follow-up in a clinical study or registry, as appropriate, for the assessment of the anti-leukaemic activity of ceplene plus low dose interleukin-2 in a sufficient number of adult patients stratified by age greater or less than 60 years with acute myeloid leukemia in first complete remission
evalwa mard minimu residwu (mrd - minimal residual disease) fil-linja bażi u segwi fi studju kliniku jew reġistru, kif xieraq, għall-valutazzjoni tal-attività antilewkimika ta’ ceplene flimkien ma’ doża baxxa ta’ interleukin-2 f’numru suffiċjenti ta’ pazjenti adulti stratifikati skont l-età bħala akbar jew inqas minn 60 sena b’lewkimja mjelojde akuta fl-ewwel remissjoni kompluta

as expected on the basis of the study design, no difference was observed in remission duration, disease-free survival or overall survival, although patients with complete molecular response and remaining in minimal residual disease had a better outcome in terms of both remission duration (p = 0.01) and disease-free survival (p = 0.02).
kif mistenni mill-mod kif ġie diżenjat dan l-istudju, ma kienx hemm differenzi fit-tul taż-żmien ta’ remissjoni, sopravivenza ħielsa mill- marda jew sopravivenza globali, għalkemm il-pazjenti b’rispons molekulari komplet u li baqgħu bir- residwu minimu tal-marda kellhom konsegwenzi aħjar kemm mil-lat taż-żmien ta’ remissjoni (p=0.01) u s-sopravivenza ħielsa mill-marda (p=0.02).